Skip to main content

Table 4 Association between brain response and systemic response in patients with brain metastasis at study entry

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Best Systemic Response Best Brain Response
CR PR Any response SD > 6 m SD < 6 m PD Total P-value*
No (%) No (%) No (%) No (%) No (%) No (%) No (%)  
CR 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.0001
PR 1 (50.0) 2 (33.3) 12 (60.0) 2 (25.0) 0 (0.0) 1 (14.3) 18 (38.3)  
SD > 6 m 0 (0.0) 0 (0.0) 3 (15.0) 6 (75.0) 1 (25.0) 0 (0.0) 10 (21.3)  
SD < 6 m 1 (50.0) 4 (66.7) 3 (15.0) 0 (0.0) 3 (75.0) 2 (28.6) 13 (27.7)  
PD 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 4 (57.1) 6 (12.8)  
Total 2 (3.7) 6 (11.1) 20 (37.0) 8 (14.8) 4 (7.4) 7 (13.0) 47 (100.0)  
  1. * The patients with evaluable response were calculated by Fisher’s exact test.
  2. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us